RGCC scientists have developed a new anti-cancer dietary supplement that’s 34% more effective than the leading brand. Led by RGCC’s Dr Ioannis Papasotiriou, the new product offers yet more evidence of the potential for dietary supplements in the battle against cancer. It also demonstrates RGCC’s cutting-edge research and discovery capabilities.
Genistein is a naturally occurring compound with proven anti-cancer properties. Taken as a supplement, Genistein acts as a chemotherapeutic agent inhibiting tumour growth and stopping cancer from spreading to the bloodstream, a process called metastasis.
While Genistein supplements are available for sale, a lack of control, guidelines, and legislation mean users can’t always be confident in receiving the recommended dose.
RGCC scientists set out to create a new Genistein capsule that would more effectively deliver a standard dose. The team developed five prototype capsules and tested them to understand how they would perform against human breast cancer cells. The peer-reviewed research was published in the prestigious journal PLOS ONE in April this year and describes how the innovative solution took shape.
In the paper, the scientists describe how the capsules disintegrate and dissolve within the human body. Next, they characterised its ‘flowability’ (how effectively the substance flows in the human body). Finally, they performed a series of experiments to check for any incompatibilities between Genistein and the material used to create the capsule.
The team continued to test the new Genistein formulation on human cell lines. Using breast cancer cells, they compared the impact of RGCC’s custom-created Genistein compound and a commercially available product. The results demonstrated the superiority of the newly created product.
“RGCC’s capsules exhibited enhanced action in human cell lines as well as impressive pharmacokinetic results in animal models,” say the authors. “Its maximum concentration in vivo was determined 34% higher than the commercial one.”
“This study proved that changes in formulation could affect the efficacy of a dosage form and enhance its properties,” conclude the authors. “This resulted in an improved product with proven activity. The enhanced properties made the product exhibited improved in vitro behavior and great pharmacokinetic profile.”
The findings support the view that regularly taking a Genistein supplement could benefit cancer patients. While dietary supplements are currently not routinely offered to patients, the researchers believe the exciting results add weight to the case for prescribing them. “Based on the literature information on Isoflavones and Genistein, doctors and physicians could recommend the daily intake of Genistein,” the authors propose.
The study is a further demonstration of RGCC’s research and development capability. RGCC scientists regularly create and contribute to life-changing research on cancer diagnostic tests and treatments.